Pyramid Biosciences’ $864 Million Licensing Deal

Ballard Spahr advised Pyramid Biosciences on the deal.

Clinical-stage biotechnology company Pyramid Biosciences, Inc. announced the development of a global licensing deal for two cancer therapies worth up to $846 million.

The licensing agreement with South Korea-based biotechnology company Voronoi, Inc. will bring a novel monopolar spindle1 (MPS1) called VRN-08 and second undisclosed asset into Pyramid Bioscience’s portfolio of precision oncology therapeutics. MPS1 is involved in core-of-tumor cell division. The novel inhibitor VRN-08 selectively blocks this process, ultimately leading to tumor cell death.

Founded in 2015, Waltham, Mass.-based Pyramid Biosciences is dedicated to developing a portfolio of precision therapies targeting a wide range of molecularly defined diseases. Voronoi Inc. is a biotechnology company that develops novel kinase inhibitors and target protein degraders. It regularly partners with companies in the United States on preclinical programs.

The Ballard Spahr team was led by John A. Zurawski (Picture), Sommer S. Zimmerman, Ph.D. and Ignacio Celis-Aguirre.

Involved fees earner: Ignacio Celis-Aguirre – Ballard Spahr LLP; Sommer Zimmerman – Ballard Spahr LLP; John Zurawski – Ballard Spahr LLP;

Law Firms: Ballard Spahr LLP;

Clients: Pyramid Biosciences, Inc.;

Martina Bellini

Author: Martina Bellini